Breaking News

Piramal Invests $10 million in Riverview Expansion

Expands High Potency API Capability to serve the growing ADC market

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Piramal Pharma Solutions (PPS) has opened a new wing at its Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs). The total investment to upgrade the site was approximately $10 million and includes the new QC/analytical lab and two kilo-labs, as well as a doubling of the office space to support the growth at the Riverview site.     To date, the Riverview site has had the containment capability and engin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters